Neurocrine Biosciences Q3 2026 Results: Net Income $206M, Down 1.4% YoY
Neurocrine Biosciences reported significant growth for the third quarter of 2026, with net product sales increasing to $1.12 billion compared to $789.9 million in the prior year. While net income for the quarter remained relatively flat at $206.5 million due to higher operating expenses and investment losses, the company's nine-month net income grew substantially to $548.8 million.
- Key figure
- Net income $206M · -1.4% YoY